Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

Wright, George L.; Haley, Cara; Beckett, Mary Lou; Schellhammer, Paul F.

doi:10.1016/1078-1439(95)00002-y

Cited by 477 publications

(337 citation statements)

References 6 publications

Supporting

Mentioning

325

Contrasting

Unclassified

Order By: Relevance

“…1). 12 The PSMA receptor has an internalisation process that allows endocytosis of bound proteins on the cell surface into an endosomal compartment, which allows PSMA labelled radioisotopes to be concentrated within the cell 13. The density of expression of this transmembrane receptor on prostate cancer cells further increases dependent on the Gleason score of the prostate cancer, and in castrate‐resistant prostate cancers, making it the ideal target for radionuclide therapy 12…”

Section: What Is Psmamentioning

confidence: 99%

Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Emmett

Willowson

Violet

et al. 2017

J of Medical Radiation Sci

247

233

View full text Add to dashboard Cite

Prostate‐specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high‐binding affinity for the PSMA receptor have allowed high quality, highly specific PET imaging, in addition to the development of targeted radionuclide therapy for men with prostate cancer. This targeted therapy for prostate cancer has, to date, predominately used Lutetium 177 (Lu) labelled PSMA peptides. Early clinical studies evaluating the safety and efficacy of Lu PSMA therapy have demonstrated promising results with a significant proportion of men with metastatic prostate cancer, who have already failed other therapies, responding clinically to Lu PSMA. This review discusses the practical issues of administering Lu PSMA, and gives an overview of the findings from currently published trials in regards to treatment response rates, expected toxicities and safety.

show abstract

Section: What Is Psmamentioning

confidence: 99%

Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Emmett

Willowson

Violet

et al. 2017

J of Medical Radiation Sci

247

233

View full text Add to dashboard Cite

show abstract

“…13,14 Prostate-specific membrane antigen is a 100 kDa transmembrane protein that was initially isolated from LnCapD prostate cancer (PCA) cells and has since been characterized as a type II integral membrane protein with a small extracellular domain. 15,16 Although this membrane protein has been identified in prostate epithelial cells, duodenal mucosa and some proximal renal tubules, as well as prostatic endothelium, 17 the majority of extra-prostatic expression of PSMA appears to be very limited, 15 thus making it hold potential promise for tumor targeting. In order to target PSMA, an anti-PSMA monoclonal antibody (mAb), J591, has already been generated and shown cellular internalization.…”

Section: Introductionmentioning

confidence: 99%

Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate

et al. 2006

View full text Add to dashboard Cite

We have utilized a novel polyethylenimine (PEI)/DNA-bgal vector to investigate the specificity and efficiency of immunotargeting prostate-specific membrane antigen (PSMA). Coupling of the PSMA-specific monoclonal antibody, J591, to the vector was facilitated via the high-affinity interaction between phenyl(di)boronic acid and salicylhydroxamic acid molecules. Highly efficient gene delivery by this prostate cancer (PCA)-targeted J591/polyethylene glycol (PEG)/PEI/ DNA-bgal vector was demonstrated in PSMA-positive cells relative to controls, resulting in significant growth inhibition in vitro when the J591/PEG/PEI/DNA-p53 was used. Competition with free antibody resulted in about 90% reduction in both J591 internalization and bgal gene delivery, indicating specificity for PSMA-positive cells. More importantly, testing the efficiency of the J591/PEG/PEI/DNA-bgal targeting vector in an orthotopic PCA model in nude mice resulted in up to a 20-fold increase in gene delivery over the untargeted vector controls. The in vivo organ distribution profile also revealed bgal expression predominantly in the tumor, which was more than 1 log higher than the next highest level of expression in the lung. Furthermore, with the targeted vector containing the gene for yellow fluorescent protein or biotinylated J591, we further demonstrate in vivo that vector-mediated gene delivery is specific for both tumor cells and tumor-associated neovasculature in PSMA-positive tumors. These results suggest the potential for further optimization of this novel vector in the context of therapeutic gene delivery. Gene Therapy (2006) 13, 761-772.

show abstract

“…Virtually all prostate cancer primary tumors express PSMA (Wright, Haley et al 1995;Murphy, Elgamal et al 1998;Kusumi, Koie et al 2008;Ananias, van den Heuvel et al 2009;Mannweiler, Amersdorfer et al 2009), whereas PSMA expressed in prostate vascular endothelium of benign tissue (Chang, O'Keefe et al 1999). PSMA levels increase progressively in higher-grade cancers, metastatic disease, hormone-refractory cancer, progressing cancer, and cancers exhibiting rising blood PSA following prostatectomy (Israeli, Miller et al 1994;Wright, Haley et al 1995;Wright, Mayer Grob et al 1996;Sweat, Pacelli et al 1998;Ross, Sheehan et al 2003;Perner, Hofer et al 2007;Minner, Wittmer et al 2011). Thus, anti-PSMA immunocapture is likely to capture circulating prostate cells independent of when cells undergo EMT.…”

Section: Introductionmentioning

confidence: 99%

Immunocapture of prostate cancer cells with anti-PSMA antibodies in microdevices

Santana

Liu

Bander

et al. 2011

2011 IEEE 37th Annual Northeast Bioengineering Conference (NEBEC)

View full text Add to dashboard Cite

Patients suffering from cancer can shed tumor cells into the bloodstream, leading to one of the most important mechanisms of metastasis. As such, the capture of these cells is of great interest. Circulating tumor cells are typically extracted from circulation through positive selection with the epithelial cell-adhesion molecule (EpCAM), leading to currently unknown biases when cells are undergoing epithelial-to-mesenchymal transition. For prostate cancer, prostate-specific membrane antigen (PSMA) presents a compelling target for immunocapture, as PSMA levels increase in higher-grade cancers and metastatic disease and are specific to the prostate epithelium. This study uses monoclonal antibodies J591 and J415-antibodies that are highly specific for intact extracellular domains of PSMA on live cells-in microfluidic devices for the capture of LNCaPs, a PSMA-expressing immortalized prostate cancer cell line, over a range of concentrations and shear stresses relevant to immunocapture. Our results show that J591 outperforms J415 and a mix of the two for prostate cancer capture, and that capture performance saturates following incubation with antibody concentrations of 10 micrograms per milliliter.

show abstract

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

Cited by 477 publications

References 6 publications

Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate

Immunocapture of prostate cancer cells with anti-PSMA antibodies in microdevices

Contact Info

Product

Resources

About

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

Cited by 477 publications

References 6 publications

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate

Immunocapture of prostate cancer cells with anti-PSMA antibodies in microdevices

Contact Info

Product

Resources

About

Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy